Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Olaptesed pegol

EU orphan designation number: EU/3/14/1364   
Active ingredient: Olaptesed pegol
Indication: Treatment of glioma
Sponsor: Noxxon Pharma AG
Max-Dohrn-Straße 8-10, 10589 Berlin, Deutschland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
21/11/2014 Orphan designation EMA/OD/132/14 (2014)8858 of 19/11/2014